Skip to main content

Advertisement

SpringerLink
Log in

Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

Nasal or extranasal natural killer/T-cell lymphoma (NKTCL) is a very rare aggressive lymphoma, but it is increasingly diagnosed. To evaluate some specificity by comparative analysis between primary upper aerodigestive tract (UAT) and non-upper aerodigestive tract (NUAT)NKTCL.

Methods

A retrospective analysis was performed on NKTCL patients from January 2013 to November 2022 in our cancer center.

Results

The majority of the lesions were UAT-NKTCL 70 cases (92.1%), the primary NUAT occurred in 6 cases. Patients in the UAT group were mainly in the early stage and in the low and medium risk, while those in the NUAT group were late stage and in high risk (p = 0.000). The expressions of CD3 and TIA-1 in UAT group were higher than those in NUAT group (p = 0.031, p = 0.003), while CD7 was dominant in NUAT group (p = 0.009). For early stage NKTCL, multivariate analysis suggested that gender and PINK score were independent factors affecting PFS and OS (p < 0.05). The 3 year OS rate in initial CR group was 90.1% versus 46.4% in non-CR group (p = 0.000). In advanced stage, KI67% and bone marrow involvement were independent factors affecting OS (p = 0.022, p = 0.038).

Conclusion

It was difficult to distinguish between UAT and NUAT-NKTCL from histopathology. NUAT-NKTCL patients did have advanced stage and poor outcome. The prognostic value of PINK score and bone marrow involvement was proposed. We aimed to improve initial CR rates, as well as to find new predictive models to predict the whole population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;22(6):77.

    Article  Google Scholar 

  2. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59(4):1127–37.

    Article  PubMed  Google Scholar 

  3. Yang Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3(1):83–91.

    Article  PubMed  Google Scholar 

  4. Boros A, Michot JM, Hoang-Xuan K, Mazeron R. Place de la radiothérapie dans la prise en charge des lymphomes NK/T de type nasal et primitifs cérébraux [Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas]. Cancer Radiother. 2016;20(6–7):535–42.

    Article  CAS  PubMed  Google Scholar 

  5. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–600.

    Article  CAS  PubMed  Google Scholar 

  6. Wu T, Yang Y, Zhu SY, Shi M, Su H, Wang Y, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018;2(18):2369–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–6.

    Article  CAS  PubMed  Google Scholar 

  8. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–80.

    Article  CAS  PubMed  Google Scholar 

  9. Liu ZL, Bi XW, Zhang XW, Lei DX, Liu PP, Yang H, et al. Characteristics, prognostic factors, and survival of patients with NK/T-Cell lymphoma of non-upper Aerodigestive Tract: A 17-year single-center experience. Cancer Res Treat. 2019;51(4):1557–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29(7):1571–7.

    Article  CAS  PubMed  Google Scholar 

  11. Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35(1):130–42.

    Article  PubMed  Google Scholar 

  12. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.

    Article  CAS  PubMed  Google Scholar 

  13. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.

    CAS  PubMed  Google Scholar 

  14. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020;21(2):306–16.

    Article  CAS  PubMed  Google Scholar 

  16. Huang Y, Chen S, Wei R, Guo X, Yang X, Cao Q, et al. CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows Arch. 2020;477(6):873–83.

    Article  CAS  PubMed  Google Scholar 

  17. Deng XW, Wu JX, Wu T, Zhu SY, Shi M, Su H, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiother Oncol. 2018;129(1):3–9.

    Article  PubMed  Google Scholar 

  18. Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018;29(1):256–63.

    Article  CAS  PubMed  Google Scholar 

  19. Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100(2):366–75.

    Article  PubMed  Google Scholar 

  20. Qi F, Zhou W, Xie Y, Sun Y, Wu M, Chai Y, et al. Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation. Aging (Albany NY). 2022;14(21):8729–44.

    Article  PubMed  Google Scholar 

  21. Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, et al. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018;109(6):2056–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yang Y, Wang Y, Liu X, He X, Zhang LL, Wu G, et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2021;35(6):1671–82.

    Article  CAS  PubMed  Google Scholar 

  23. Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Lymphoma subcommittee of the Korean cancer study group clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type a national survey of the Korean cancer study group. Ann Oncol. 2008;19(8):1477–84.

    Article  CAS  PubMed  Google Scholar 

  24. Alonso-Álvarez S, Alcoceba M, García-Álvarez M, Blanco O, Rodríguez M, Baile M, et al. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large B-cell lymphoma. Cancers (Basel). 2020;12(2):474.

    Article  PubMed  Google Scholar 

  25. He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;5(14):153.

    Article  Google Scholar 

  26. Wang JH, Wang H, Wang YJ, Xia ZJ, Huang HQ, Jiang WQ, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget. 2016;7(23):35412–22.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Cai J, Liu P, Huang H, Li Y, Ma S, Zhou H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020;5(1):289.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Du L, Zhang L, Li L, Li X, Yan J, Wang X, et al. Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for relapsed/refractory natural killer/T-Cell lymphoma: a report of three cases. Onco Targets Ther. 2020;27(13):7189–97.

    Article  Google Scholar 

  29. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–64.

    Article  PubMed  Google Scholar 

  30. Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Renmin Hospital of Wuhan University, Hubei, 430060, People’s Republic of China

    Xiaohong Liu, Dedong Cao, Xin Liu & Ximing Xu

  2. Department of Hematology, Renmin Hospital of Wuhan University, Hubei, 430060, People’s Republic of China

    Hui Liu

  3. Department of Pathology, Renmin Hospital of Wuhan University, Hubei, 430060, People’s Republic of China

    XiaoKang Ke

Authors
  1. Xiaohong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dedong Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. XiaoKang Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ximing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Ximing Xu.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics approval and informed consent

This study was approved by the Medical Ethics Committee of Renmin Hospital of Wuhan University (number WDRY2021-KS024). The requirement for written informed consent was waived off due to the retrospective nature of the study. The consent waiver was approved via IRB. All data used in this manuscript were anonymized.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Cao, D., Liu, H. et al. Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma. Clin Transl Oncol 26, 214–224 (2024). https://doi.org/10.1007/s12094-023-03238-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03238-x

Keywords

Search

Navigation